“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert ...

Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in two trials.

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial data showed.

Long-term data from the VISIONARY-MS Phase 2 trial links improved brain imaging and visual evoked potentials to remyelination and neuronal repair in MS patients treated with CNM-Au8.

DMD treatment KER-065 showed a good safety profile in a Phase 1 clinical trial with no serious side effects seen in healthy ...